ALNY — Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Global Net Product Revenues: Approximately $1.2 billion, a 74% increase year-over-year, marking the first quarter AMVUTTRA revenues exceeded $1 billion.
• TTR Revenues: $1.03 billion, reflecting an 89% year-over-year increase.
• Collaboration Revenue: $47 million, a 23% decrease due to lower revenue from Regeneron, partially offset by increased revenue from Roche.
• Royalty Revenue: Increased by 79% to $72 million, driven by higher LEQVIO sales by Novartis.
• Gross Margin: 75%, down 4% from Q2 last year, primarily due to increased royalties on AMVUTTRA.
• Non-GAAP R&D Expenses: $377 million, a 38% increase, driven by ongoing Phase III studies.
• Non-GAAP SG&A Expenses: $297 million, a 14% increase, primarily for AMVUTTRA launch support.
• Non-GAAP Operating Income: $318 million, more than triple last year’s figure.
• Cash Position: $3.3 billion, up from $2.9 billion at year-end 2025.

2. Strategic Updates and Business Highlights

• AMVUTTRA Launch: Strong performance with a focus on first-line treatment, which now accounts for about 80% of new patient starts.
• Geographic Expansion: Collaboration with BeOne for exclusive commercialization rights in Mainland China and Macau.
• AI Collaborations: New partnerships to enhance disease identification and therapeutic discovery.
• Pipeline Development: Initiated Phase II trials for ALN-6400 and mivelsiran, with key data readouts expected in the second half of 2026.

3. Forward Guidance and Outlook

• Revised 2026 Revenue Guidance: Total net product revenue expected to be between $4.7 billion and $5.1 billion, with TTR revenue guidance lowered to $4.2 billion to $4.5 billion, reflecting a $200 million reduction due to normalization of second-line demand.
• Long-term Growth Confidence: Despite the guidance reduction, management remains confident in achieving a 25% CAGR through 2030, supported by strong first-line demand and market fundamentals.

4. Bad News, Challenges, or Points of Concern

• Guidance Reduction: Lowered revenue guidance due to a better understanding of second-line demand normalization, which was initially overestimated.
• Competitive Landscape: Negative outcomes from the CARDIO-TTRansform study of eplontersen raise concerns about competitive pressures, although management remains confident in TRITON-CM for nucresiran.
• Market Dynamics: Potential challenges in maintaining growth rates as the market stabilizes and competition increases, particularly with generic entries anticipated in the future.

5. Notable Q&A Insights

• Market Dynamics: Management emphasized the importance of early diagnosis and the potential for increased patient capture in the first-line setting, with 80% of patients still untreated.
• Physician Education: There is a focus on educating community physicians about the differences between silencers and stabilizers to maintain growth in first-line starts.
• Impact of Competitor Data: Management does not expect significant changes in AMVUTTRA's market access due to the results of the CARDIO-TTRansform study, asserting that it does not affect AMVUTTRA's efficacy or label.
• Long-term Confidence: Despite challenges, management expressed increased confidence in future growth driven by strong fundamentals and the opportunity to expand the prescriber base.

Overall, Alnylam Pharmaceuticals reported strong financial results for Q2 2026, with significant growth in AMVUTTRA revenues. However, the company revised its revenue guidance downward due to normalization of second-line demand, while maintaining confidence in long-term growth prospects and strategic initiatives.